Tegoprazan
Identification
- Generic Name
- Tegoprazan
- DrugBank Accession Number
- DB16690
- Background
Tegoprazan (also known as CJ-12420) is a novel therapeutic developed by CJ Healthcare Corp for treating acid-related gastrointestinal diseases.1,2 This drug is a potent and high-selective potassium-competitive acid blocker (P-CAB) with a fast onset of action and the ability to control gastric pH for a prolonged period of time.1,2 Tegoprazan’s strong and sustained effect is due to its ability to be slowly cleared from the gastric glands and exertion of effects independent of acid levels.2 It has also been observed to be efficacious independent of food intake.2
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 387.387
Monoisotopic: 387.13944781 - Chemical Formula
- C20H19F2N3O3
- Synonyms
- CJ-12420
- IN-A001
- K-CAB
- LXI-15028
- RQ-00000004
- Tegoprazan
- External IDs
- CJ-12420
- LXI-15028
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Tegoprazan works as a potassium-competitive acid blocker that is potent and highly selective.1,2 Its mechanism of action is different from that of the proton-pump inhibitors as this drug does not require conversion into an active form and can directly inhibit H+/K+‐ATPase in a reversible and K+‐competitive way.2 This is because it is an acid-resistant weak base with the ability to remain in the highly acidic canaliculi of gastric parietal cells.2
Target Actions Organism ASodium/Potassium Transporting ATPase inhibitorHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAlendronic acid The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Tegoprazan. Amphetamine Tegoprazan can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects. Amprenavir Tegoprazan can cause a decrease in the absorption of Amprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy. Asunaprevir Tegoprazan can cause a decrease in the absorption of Asunaprevir resulting in a reduced serum concentration and potentially a decrease in efficacy. Atazanavir Tegoprazan can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- ATC Codes
- A02BC09 — Tegoprazan
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- W017G7IF4S
- CAS number
- 942195-55-3
- InChI Key
- CLIQCDHNPDMGSL-HNNXBMFYSA-N
- InChI
- InChI=1S/C20H19F2N3O3/c1-10-23-14-6-11(20(26)25(2)3)7-17(19(14)24-10)28-15-4-5-27-16-9-12(21)8-13(22)18(15)16/h6-9,15H,4-5H2,1-3H3,(H,23,24)/t15-/m0/s1
- IUPAC Name
- 7-{[(4S)-5,7-difluoro-3,4-dihydro-2H-1-benzopyran-4-yl]oxy}-N,N,2-trimethyl-1H-1,3-benzodiazole-5-carboxamide
- SMILES
- CN(C)C(=O)C1=CC(O[C@H]2CCOC3=CC(F)=CC(F)=C23)=C2NC(C)=NC2=C1
References
- General References
- Kim DK, Lee KH, Kim SJ, Kim SJ, Lee SJ, Park CH, Kim BT, Song GS, Moon BS, Ryu SY: Effects of Tegoprazan, a Novel Potassium-Competitive Acid Blocker, on Rat Models of Gastric Acid-Related Disease. J Pharmacol Exp Ther. 2019 Jun;369(3):318-327. doi: 10.1124/jpet.118.254904. Epub 2019 Mar 20. [Article]
- Lee KJ, Son BK, Kim GH, Jung HK, Jung HY, Chung IK, Sung IK, Kim JI, Kim JH, Lee JS, Kwon JG, Park JH, Huh KC, Park KS, Park MI, Kim N, Lee OY, Jee SR, Lee SK, Youn SJ, Kim SK, Lee ST, Hong SJ, Choi SC, Kim TN, Youn YH, Park HJ, Kang MJ, Park CH, Kim BT, Youn S, Song GS, Rhee PL: Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. Aliment Pharmacol Ther. 2019 Apr;49(7):864-872. doi: 10.1111/apt.15185. Epub 2019 Mar 6. [Article]
- External Links
- ChemSpider
- 44209499
- ChEMBL
- CHEMBL4297583
- PDBe Ligand
- 8BN
- PDB Entries
- 7w47
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Active Not Recruiting Treatment Helicobacter Pylori Infection / Proton Pump Inhibitors / Vonoprazan 1 4 Completed Treatment Erosive Reflux Disease 2 4 Not Yet Recruiting Treatment Helicobacter Pylori Infection 2 4 Recruiting Treatment Gastro-esophageal Reflux Disease (GERD) 1 4 Recruiting Treatment Helicobacter Pylori-positive With Functional Dyspepsia 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral 50.000 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0453 mg/mL ALOGPS logP 2.91 ALOGPS logP 2.32 Chemaxon logS -3.9 ALOGPS pKa (Strongest Acidic) 11.37 Chemaxon pKa (Strongest Basic) 6.07 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 67.45 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 98.82 m3·mol-1 Chemaxon Polarizability 38.71 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-014r-0539000000-62df24d7c2bd6abf457f Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-014r-0719000000-467509b00f58aa14a333 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-000i-0009000000-4d86510ba2bc78330eaa Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-00xs-0933000000-96ef75fccf56a91eb861 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0a6s-0916000000-ea1209af3f141debdda4 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-066s-2945000000-5539415411484d3464d0 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Targets
- Kind
- Protein group
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Steroid hormone binding
- Specific Function
- This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates th...
Components:
References
- Lee KJ, Son BK, Kim GH, Jung HK, Jung HY, Chung IK, Sung IK, Kim JI, Kim JH, Lee JS, Kwon JG, Park JH, Huh KC, Park KS, Park MI, Kim N, Lee OY, Jee SR, Lee SK, Youn SJ, Kim SK, Lee ST, Hong SJ, Choi SC, Kim TN, Youn YH, Park HJ, Kang MJ, Park CH, Kim BT, Youn S, Song GS, Rhee PL: Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. Aliment Pharmacol Ther. 2019 Apr;49(7):864-872. doi: 10.1111/apt.15185. Epub 2019 Mar 6. [Article]
Drug created at April 26, 2021 17:31 / Updated at April 30, 2021 13:08